Ipsen pulls cancer drug Tazverik from market over safety risks

Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...

AI Summary: Ipsen has removed its EZH2 inhibitor Tazverik (tazemetostat) from the U.S. market after safety issues flagged by an independent monitoring review. The withdrawal forces clinicians to pivot to alternative therapies and triggers regulatory and clinical re‑examination of the drug’s benefit‑risk profile for patients previously depending on it.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 15 days

Atezolizumab added to chemoradiation fails to improve limited‑stage SCLC survival / 2 months

HORMAD1 emerges as a potential target in triple‑negative breast cancer / 2 months

Roche’s hoped‑for breast cancer pill fails crucial first‑line trial / 2 months

Romiplostim prevents chemo-induced platelet crashes in phase 3 trial / 2 months

Datroway secures regulatory approvals in breast cancer across US and EU / 8 days

FDA clears first targeted therapy for ultra-rare NRG1-driven cholangiocarcinoma / 20 days